The group discontinues its first-generation antisense Huntington’s projects on disappointing efficacy, leaving its next-gen asset with much to prove.
The failure of Roche and Ionis’s late-stage candidate tominersen casts doubt on Wave’s approach, too.
The group hopes for a better result with a higher dose of its antisense projects, but it also has a back-up plan.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.
Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.
The most important clinical readouts of the holiday period concerned Google Health, Axsome, Wave and Spectrum.
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…